{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:55Z","timestamp":1790155735314,"version":"4.0.1"},"reference-count":59,"publisher":"Impact Journals, LLC","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,12,27]]},"DOI":"10.18632\/oncotarget.13552","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T18:38:50Z","timestamp":1480012730000},"page":"87161-87179","source":"Crossref","is-referenced-by-count":26,"title":["Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation"],"prefix":"10.18632","volume":"7","author":[{"given":"Yueh","family":"Chien","sequence":"first","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Pharmacology, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chian-Shiu","family":"Chien","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Pharmacology, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huai-Chih","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Pharmacology, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Lin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Anatomy and Cell Biology, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jie","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Pharmacology, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chao","family":"Chang","sequence":"additional","affiliation":[{"name":"Graduate Institute of Cancer Biology and Center for Molecular Medicine, China Medical University and Department of Biotechnology, Asia University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Lih","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Pharmacology, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Bang","family":"Leu","sequence":"additional","affiliation":[{"name":"Division of Cardiology & Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Hsuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Cardiology & Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Hsiu","family":"Lai","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Hsi","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Cheng-Hsin Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Anatomy and Cell Biology, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Jen","family":"Sung","sequence":"additional","affiliation":[{"name":"Institute of Anatomy and Cell Biology, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Jyh","family":"Jong","sequence":"additional","affiliation":[{"name":"College of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann-Jang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Institute of Genome Sciences, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Genomics Research Center, Academia Sinica, Taipei, Taiwan"},{"name":"Department of Chemistry, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chung","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Cardiology & Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,24]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Strotmann","year":"2009","journal-title":"Circulation"},{"key":"3","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2010.08.006","article-title":"Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease","volume":"399","author":"Sakuraba","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease\u2014role of urine globotriaosylceramide","volume":"28","author":"Deegan","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels","volume":"30","author":"Hollak","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13023-014-0111-y","article-title":"Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)","volume":"9","author":"Niu","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2119\/molmed.2014.00034","article-title":"Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure","volume":"20","author":"Toldo","year":"2014","journal-title":"Mol Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-065X.2008.00624.x","article-title":"IL-1, IL-18, and IL-33 families of cytokines","volume":"223","author":"Gabay","year":"2008","journal-title":"Immunol Rev"},{"key":"9","doi-asserted-by":"crossref","first-page":"29445","DOI":"10.1074\/jbc.273.45.29445","article-title":"Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling","volume":"273","author":"Sims","year":"1998","journal-title":"J Biol Chem"},{"key":"10","doi-asserted-by":"crossref","first-page":"25737","DOI":"10.1074\/jbc.272.41.25737","article-title":"Purification and characterization of the human interleukin-18 receptor","volume":"272","author":"Ikegami","year":"1997","journal-title":"J Biol Chem"},{"key":"11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/378088a0","article-title":"Cloning of a new cytokine that induces IFN-gamma production by T cells","volume":"378","author":"Hattori","year":"1995","journal-title":"Nature"},{"key":"12","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/jlb.63.6.658","article-title":"Overview of interleukin-18: more than an interferon-gamma inducing factor","volume":"63","author":"Rubinstein","year":"1998","journal-title":"J Leukoc Biol"},{"key":"13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/SHK.0b013e318160f215","article-title":"Interleukin 18 in the heart","volume":"30","author":"Meldrum","year":"2008","journal-title":"Shock"},{"key":"14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/0267659108101511","article-title":"The effect of daily administration of IL-18 on cardiac structure and function","volume":"23","author":"Larson","year":"2008","journal-title":"Perfusion"},{"key":"15","doi-asserted-by":"crossref","first-page":"H76","DOI":"10.1152\/ajpheart.01285.2008","article-title":"IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice","volume":"297","author":"Larson","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"16","doi-asserted-by":"crossref","first-page":"7853","DOI":"10.1074\/jbc.M808824200","article-title":"Neutralization of interleukin-18 ameliorates ischemia\/reperfusion-induced myocardial injury","volume":"284","author":"Chandrasekar","year":"2009","journal-title":"J Biol Chem"},{"key":"17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/heart.88.5.467","article-title":"Increased plasma concentrations of interleukin-18 in acute coronary syndromes","volume":"88","author":"Tedgui","year":"2002","journal-title":"Heart"},{"key":"18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/heart.88.3.296","article-title":"Increased circulating interleukin-18 in patients with congestive heart failure","volume":"88","author":"Iwasaki","year":"2002","journal-title":"Heart"},{"key":"19","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1096\/fj.04-2426fje","article-title":"Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure","volume":"18","author":"Tedgui","year":"2004","journal-title":"FASEB J"},{"key":"20","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1016\/j.biomaterials.2012.07.029","article-title":"Corneal repair by human corneal keratocyte-reprogrammed iPSCs and amphiphatic carboxymethyl-hexanoyl chitosan hydrogel","volume":"33","author":"Chiou","year":"2012","journal-title":"Biomaterials"},{"key":"21","doi-asserted-by":"crossref","first-page":"23661","DOI":"10.1038\/srep23661","article-title":"Impaired ROS Scavenging System in Human Induced Pluripotent Stem Cells Generated from Patients with MERRF Syndrome","volume":"6","author":"Chiou","year":"2016","journal-title":"Sci Rep"},{"key":"22","first-page":"191","article-title":"The generation of induced pluripotent stem cells for macular degeneration as a drug screening platform: identification of curcumin as a protective agent for retinal pigment epithelial cells against oxidative stress","volume":"6","author":"Peng","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nature10761","article-title":"The promise of induced pluripotent stem cells in research and therapy","volume":"481","author":"Daley","year":"2012","journal-title":"Nature"},{"key":"24","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.celrep.2014.09.055","article-title":"Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells","volume":"9","author":"Kiialainen","year":"2014","journal-title":"Cell Rep"},{"key":"25","doi-asserted-by":"crossref","first-page":"e0131511","DOI":"10.1371\/journal.pone.0131511","article-title":"Cardiac engraftment of genetically-selected parthenogenetic stem cell-derived cardiomyocytes","volume":"10","author":"Field","year":"2015","journal-title":"PLoS One"},{"key":"26","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1161\/CIRCULATIONAHA.113.001883","article-title":"Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity","volume":"127","author":"Robbins","year":"2013","journal-title":"Circulation"},{"key":"27","article-title":"High throughput physiological screening of iPSC-derived cardiomyocytes for drug development","author":"Mercola","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/cvr\/cvu205","article-title":"Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells","volume":"104","author":"Yang","year":"2014","journal-title":"Cardiovasc Res"},{"key":"29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/HCO.0000000000000049","article-title":"Human-induced pluripotent stem cell models of inherited cardiomyopathies","volume":"29","author":"Wu","year":"2014","journal-title":"Curr Opin Cardiol"},{"key":"30","doi-asserted-by":"crossref","first-page":"15023","DOI":"10.1038\/mtm.2015.23","article-title":"Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient","volume":"2","author":"Ohashi","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"key":"31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10545-014-9724-5","article-title":"Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease","volume":"37","author":"Orsini","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"32","doi-asserted-by":"crossref","first-page":"e108051","DOI":"10.1371\/journal.pone.0108051","article-title":"RNA expression profiling of human iPSC-derived cardiomyocytes in a cardiac hypertrophy model","volume":"9","author":"Broeckel","year":"2014","journal-title":"PLoS One"},{"key":"33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12015-010-9224-4","article-title":"An improved technique for chromosomal analysis of human ES and iPS cells","volume":"7","author":"Volpi","year":"2011","journal-title":"Stem cell reviews"},{"key":"34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10545-015-9886-9","article-title":"Mannose receptor-mediated delivery of moss-made alpha-galactosidase A efficiently corrects enzyme deficiency in Fabry mice","volume":"39","author":"Schaaf","year":"2016","journal-title":"J Inherit Metab Dis"},{"key":"35","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI114027","article-title":"Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene","volume":"83","author":"Desnick","year":"1989","journal-title":"J Clin Invest"},{"key":"36","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/hmg\/3.10.1795","article-title":"Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene","volume":"3","author":"Desnick","year":"1994","journal-title":"Hum Mol Genet"},{"key":"37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease","volume":"345","author":"Desnick","year":"2001","journal-title":"N Engl J Med"},{"key":"38","first-page":"1221 e1221","article-title":"Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy With Enzyme Replacement Therapy","volume":"32","author":"Yu","year":"2016","journal-title":"Can J Cardiol"},{"key":"39","first-page":"1557","article-title":"Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy","volume":"23","author":"Madeira","year":"2004","journal-title":"Rev Port Cardiol"},{"key":"40","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1161\/CIRCULATIONAHA.112.000570","article-title":"Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays","volume":"128","author":"Wu","year":"2013","journal-title":"Circulation"},{"key":"41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","article-title":"Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years\u2019 treatment","volume":"10","author":"Beck","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1750-1172-9-96","article-title":"Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A)","volume":"9","author":"Chiang","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"43","first-page":"317","article-title":"Fabry disease: clinical features and recent advances in enzyme replacement therapy","volume":"31","author":"Wasserstein","year":"2001","journal-title":"Adv Nephrol Necker Hosp"},{"key":"44","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Cox-Brinkman","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"45","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2119\/molmed.2012.00002","article-title":"Fabry disease: incidence of the common later-onset alpha-galactosidase A IVS4+919G\u2014>A mutation in Taiwanese newborns\u2014superiority of DNA-based to enzyme-based newborn screening for common mutations","volume":"18","author":"Hwu","year":"2012","journal-title":"Mol Med"},{"key":"46","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/339431","article-title":"Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype","volume":"70","author":"Fan","year":"2002","journal-title":"Am J Hum Genet"},{"key":"47","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hsu","year":"2009","journal-title":"Hum Mutat"},{"key":"48","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"alpha-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Kulkarni","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"49","first-page":"289","article-title":"Interleukin-18 and IL-18 binding protein","volume":"4","author":"Kaplanski","year":"2013","journal-title":"Front Immunol"},{"key":"50","doi-asserted-by":"crossref","first-page":"H650","DOI":"10.1152\/ajpheart.00043.2002","article-title":"Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction","volume":"283","author":"Meng","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"51","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.4049\/jimmunol.1101284","article-title":"Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus","volume":"187","author":"Kaplan","year":"2011","journal-title":"J Immunol"},{"key":"52","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.105.602714","article-title":"Neutralization of interleukin-18 inhibits neointimal formation in a rat model of vascular injury","volume":"114","author":"Ialenti","year":"2006","journal-title":"Circulation"},{"key":"53","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/tri.12683","article-title":"The protective role of interleukin-18 binding protein in a murine model of cardiac ischemia\/reperfusion injury","volume":"28","author":"Lv","year":"2015","journal-title":"Transpl Int"},{"key":"54","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/apha.12376","article-title":"IL-18 neutralization during alveolar hypoxia improves left ventricular diastolic function in mice","volume":"213","author":"Christensen","year":"2015","journal-title":"Acta Physiol (Oxf)"},{"key":"55","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Guffon","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"56","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"O\u2019Callaghan","year":"2009","journal-title":"Circulation"},{"key":"57","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00428-008-0586-9","article-title":"Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients","volume":"452","author":"Elleder","year":"2008","journal-title":"Virchows Arch"},{"key":"58","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4161\/auto.6.5.11943","article-title":"Autophagosome maturation is impaired in Fabry disease","volume":"6","author":"Bekri","year":"2010","journal-title":"Autophagy"},{"key":"59","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","article-title":"Onset and progression of the Anderson-Fabry disease related cardiomyopathy","volume":"130","author":"Beck","year":"2008","journal-title":"Int J Cardiol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T13:53:45Z","timestamp":1601214825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,24]]},"references-count":59,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2016,12,27]]}},"alternative-id":["13552","27888626"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13552","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,24]]}}}